ABSTRACT Complement-stimulated granulocytes adhere to and induce significant 51Cr release from endothelial cells in vitro. Platelets were stimulated to undergo release, and these release products significantly enhanced granulocyte-endothelial cell adherence and granulocyte-induced 5tCr release from endothelial cells. Platelet serotonin appeared to mediate these phenomena because serotonin antagonists blocked both the enhanced endothelial adherence and 5tCr release. In addition, added serotonin mimicked the effect seen with the stimulated platelets upon granulocyte-endothelial cell adherence and cytotoxicity completely. This enhancement appeared to be due to serotonin effects upon both the granulocyte and endothelial cells. These data suggest that a released platelet constituent might modulate in vivo granulocyte-endothelial cell interactions in clinical disorders.
Endothelial injury, followed by subendothelial cell proliferation, is thought to play a prominent role in virtually all models of vascular injury and atherogenesis (1) . Speculation on the etiology ofthe proliferative response has centered upon the role of platelet-derived "growth factors" (2) ; however, the mechanisms for initiating endothelial cell damage have been given less attention. Recent studies from our laboratory have focused upon the damaging effects on the vascular endothelium of granulocytes (polymorphonuclear leukocytes) that have been stimulated by various immunologic stimuli, particularly activated complement components (3) . These studies were fostered by our interest in the acute pulmonary dysfunction that occurs early in hemodialysis (4) . Abnormalities in pulmonary dynamics that hemodialyzed patients manifest also may be reproduced in laboratory animals by reinfusing them with autologous plasma that had been allowed to contact hemodialyzer membranes (5, 6) ; pulmonary microvascular damage and associated pulmonary interstitial edema were evident in these animals (5, 6) .
By visualizing the microvasculature of rat mesenteries through laser intravital microscopy, Hammerschmidt et al (7) observed that infused complement, particularly C5a, first promoted granulocyte adhesion to endothelium, followed shortly thereafter by plasma leak into interstitial tissues (7) . A potential mechanism for this vascular damage was suggested by in vitro studies ofcultured endothelial cells (8) . When exposed to granulocytes and a source of activated complement, labeled endothelial cells released chromium, and this release was largely inhibited by superoxide dismutase and catalase. It appeared likely, therefore, that the complement-stimulated production of reactive oxygen species by granulocytes underlies the endothelial cell alteration, a surmise validated by recent studies of others (9) .
Because platelets and their products have been suggested as important effectors in atherogenesis-possibly in proliferative response of injured vessels-we undertook the present in vitro studies to determine their possible role in complement-mediated vascular injury. This report indicates that platelets, although ineffectual alone, exacerbate the release of radioactive label from cultured endothelial cells exposed to complementcoated particles with granulocytes. One mediator of this amplification appears to be the platelet constituent, serotonin, which we find enhances the adhesion of complement-stimulated granulocytes to their target endothelial cells. The results, reported preliminarily elsewhere (10) , suggest that platelets may play an endothelium-damaging role in addition to their previously suspected effects ofinciting vascular wall proliferation.
METHODS AND MATERIALS Preparation of Endothelial Cells. Endothelial cells were grown in culture in microtiter wells by our previously reported modification of established methods (8, 11, 12) . Cells were cultured under 95% air/5% CO2 at 370C in medium 199 containing 20% calf serum (GIBCO); they were used =5 days after explanation, just prior to reaching confluence, and were identified as endothelium by their reaction with rabbit antisera to human Factor VIII antigen (13) (Boehringer Corporation, New York, NY). In selected studies, the cultured cells were incubated with sodium arachidonate (100 uM) or thrombin (1 unit/ml) for 5 min; the supernatant fluid was then aspirated and assayed for the stable prostacyclin metabolite 6-keto-prostaglandin F1. by using a radioimmunoassay (New England Nuclear).
Blood Cell Preparation. Granulocytes were harvested from heparin-treated (6-8 unit/ml) volunteer peripheral blood by using standard techniques of dextran sedimentation, hypotonic lysis, and Ficoll/Hypaque sedimentation (8, 14) . The enriched granulocytes were washed and resuspended (final concentration, 1 x 107 cells per ml) in Hanks' balanced salt solution (Microbiological Associates, Walkersville, MD) containing 0.5% human albumin. The purified granulocytes contained 5-10% mononuclear cells and < 1 x 10 platelets per ml. Platelets were harvested from citrated (0.36%) peripheral blood by centrifugation (400 g for 5 min) to yield platelet-rich plasma (PRP). "Purified platelets" were obtained by centrifugation of PRP (1,400 x g for 10 min), with resuspension in Ca/Mg-free Hanks Determination of 51Cr Release. Endothelial cells were labeled by addition of 5 uCi (1 Ci = 3.7 x 10'°becquerels) Na251CrO4 (New England Nuclear) to serum-free medium 16 hr before planned experiments (8, 11 (8, 11) had demonstrated that resting granulocytes or activated serum complement, when added separately, do not induce significant 51Cr leak; this was confirmed in the present study.
The validity of using 51Cr release as a marker of endothelial cell alteration was strengthened by using another cell label,
[I4C]thymidine, which was preincorporated into endothelial cells for 72 hr prior to the experiment. In both situations, the released supernatant radioactivity (51Cr or 14C) was expressed as a percentage of the total cell plus supernatant fluid radioactivity recovered from each well.
Granulocyte Adherence Assay. Purified granulocytes (5 x 106) were placed atop either endothelial cells or "naked" plastic microtiter tissue culture wells (201 mm2, Costar, Cambridge, MA) in the presence of Hanks' balanced salt solution with albumin (0.5%) or in this same buffer containing 15% (vol/vol) heated or zymosan-activated serum. After incubation for 30 min at 37°C, nonadherent cells were removed by vigorous aspiration and two additional washes. Adherent granulocytes were then removed with trypsin/EDTA; microscopic inspection revealed recovery of all granulocytes. The myeloperoxidase activity in both the pooled aspirates and adherent fractions was then determined by standard techniques (11, 15) ; the percentage adherence was calculated by dividing the myeloperoxidase activity of the adherent fraction by the total activity recoverable in each well. Recovery of myeloperoxidase activity was close to 100% of that predicted, and endothelial cells contained no demonstrable myeloperoxidase activity.
Granulocyte Function Studies. Granulocyte superoxide anion (O-) was determined by the capacity of o-to reduce ferricytochrome c, as previously described by Goldstein et al (16) . Release of H202 by purified granulocytes was assayed by using the decrease in fluorescence intensity of scopoletin due to its peroxidase-mediated oxidation by H202 (11, 17) . cAMP levels were determined by radioimmunoassay (New England Nuclear) with purified granulocytes after their exposure to serotonin. After incubation at 370C for various periods of time, the reactions were terminated by placing the tubes in boiling water (5 min), and extracting the cells by freezing and thawing in distilled water. Protein was measured by the method of Lowry et al. (18) . Neutrophil hexose monophosphate-shunt activity was determined in granulocytes incubated with 1 ACi of D- [1- '4C]glucose (New England Nuclear) as described by De- Chatelet et al. (19) .
RESULTS
Platelets Amplify Granulocyte-Mediated Release of Endothelial Radiolabel. In confirmation of our earlier studies (8, 11) , endothelial cells exposed to granulocytes that are stimulated by activated complement-either as zymosan-activated plasma (not shown) or as zymosan particles opsonized by serum complement components (shown in Table 1 )-released significant amounts of Na251CrO4 (Table 1 , line 2). To determine the possible role of circulating blood cells other than granulocytes, we exposed 1 x 107 cells from whole "buffy coat," rather than density-separated granulocytes, to opsonized zymosan and then added this stimulated, mixed cell population to the labeled endothelial cells; "buffy coat" cells induced roughly a 2-fold increase (P < 0.01) in specific 51Cr release from the endothelial cells compared to that noted with more purified granulocytes ( Table 1 , line 3). The augmented specific 51Cr release probably reflects the presence of platelets in the "buffy coat" because addition of PRP in quantities adjusted to the same approximate platelet radioactivity as that in "buffy coats" produced a similar amplification of endothelial cell 51Cr release (Table 1 , line 4). However, complement-triggered platelets alone-that is, without added granulocytes but in the presence of activated complement-induced no significant 5"Cr release (Table 1 , line 5).
"Purified platelets" (PRP further enriched in platelets by recentrifugation) amplified endothelial 51Cr release to a similar degree (results not shown). Furthermore, the concentration of added platelets was critical, with no significant amplification of 51Cr release seen with <1 X 108 platelets and only a slightly increased release (12.1 ± 1.3%) when the platelet concentration was increased 3-fold (6 X 108).
In ancillary studies, we noted that the platelet amplification phenomenon was only discernable if complement-opsonized particles, but not fluid-phase complement (e.g., plasma after removal of zymosan particles), were present in the system. Others have demonstrated that particulate-but not fluid-phase activated complement causes the release reaction in human platelets (20) (21) (22) . We confirmed this observation; release ofserotonin from labeled platelets engendered by particulate activated complement ranged between 35% and 57% in five separate experiments, whereas there was virtually no release when fluid-phase complement was used to stimulate platelets labeled with 14C serotonin. Therefore, we postulated that a secreted platelet product was the amplifier of granulocyte-mediated, endothelial 51Cr release. Indeed, centrifuged supernatants of platelets that had undergone release by exposure to opsonized zymosan particles potently amplified endothelial 51Cr release (Table 1 , line 6), whereas the "spent" platelet pellet was without effect ( Identification of the Platelet-Derived Amplifier. Two separate lines of evidence indicate that serotonin (5-hydroxytryptamine) may be at least one platelet-derived amplifier of granulocyte-mediated 51Cr release. When imipramine, an inhibitor of serotonin uptake, or methysergide, a serotonin competitive inhibitor, were added to platelet release products, these then failed to amplify granulocyte-induced 51Cr release (Fig. 1 Left) .
Moreover, serotonin itself amplified granulocyte-mediated release from endothelial cells. This amplified release also could be blocked by including the same concentrations ofimipramine or methysergide (Fig. 1 Right) in the mixture of serotonin and stimulated granulocytes. However, serotonin in the absence of stimulated granulocytes did not cause endothelial injury (<2% specific 51Cr release, n = 5).
Serotonin amplified endothelial chromium release induced by activated granulocytes in a dose-dependent fashion; clearly detectable amplification was observed at 0.1 ,AM, and maximal effects were noted between 0.5 and 1 ,M (Fig. 2) . Confirmatory results were obtained with [t4C]thymidine as the endothelial cell label: unstimulated-granulocytes provoked 1.6 ± 0.5% release of this label (as trichloroacetic acid-precipitable radioactivity), which increased to 6.5 ± 1.1% with addition of opsonized zymosan and further increased to 15.5 ± 1.6% in the presence of serotonin (1 /.LM).
Mechanism of Serotonin Amplification. Our previous studies showed that granulocyte-mediated damage to endothelial cells requires close apposition ofeffector and target cells-probably because the reactive oxygen species generated by complemented-stimulated granulocytes are rapidly dissipated (8, 11) . Serotonin significantly enhanced adhesion of granulocytes (whether complement-stimulated or not) to endothelium but not to plastic (Table 2) , providing one plausible mechanism for its augmentation of endothelial cytotoxicity. The augmentation of granulocyte adherence induced by serotonin was prevented by methysergide or imipramine (not shown). These inhibitors did not retard granulocyte adherence when serotonin was not present. In addition, a modest stimulation ofgranulocyte hexose monophosphate-shunt activity by serotonin (Table 2) might contribute also to its potentiating effects because increments in this metabolic pathway generally connote increased granulocyte production ofreactive oxygen species. However, and somewhat surprisingly, we could not detect a serotonin-linked increment in superoxide anion or H202 generation in either unstimulated or complement-activated. granulocytes (Table 2) . Moreover, serotonin did not provoke detectable release of the granulocyte lysosomal enzymes, lysozyme, or myeloperoxidase (results not shown); other granulocyte lysosomal enzymes were not assayed. (1 AM), or methysergide (100 ,uM) for 15 min in the indicated experiments, and then the granulocytes were added. This mixture (PMN, platelet release products, or 5HT, and inhibitors) was then added to the endothelial cells. 
DISCUSSION
We have shown that complement-activated granulocytes adhere to and damage endothelial cells in vitro (8, 11) and microvasculature in vivo as well (3, (5) (6) (7) . Other circulating blood cells also may affect granulocyte-endothelial cell interactions, but the present in vitro studies suggest that platelets augment this toxicity through release of their granule constituents, such as serotonin or one of its metabolites. That other platelet constituents also may interact with granulocytes and render them more cytotoxic has not been excluded and may be important. For instance, platelets amplify granulocyte adherence to nylon fibers (23) , and others have shown platelet Factor IV can increase the activity of granulocyte proteases such as elastase (24) . Moreover, evidence has been provided that thrombin-stimulated but not resting platelets (in the presence of endotoxin) enhance granulocyte adherence to nylon fibers (25) , further implicating constituents ofthe platelet-release reaction in granulocyte function. Nevertheless, our ability to completely abrogate the platelet-augmenting effect on granulocyte-mediated endothelial radiolabel release with two serotonin antagonists, imipramine and methysergide (Fig. 1) (1982) ,., I or release; as a result, potentially toxic granulocytes may more readily adhere to and damage the endothelium.
The temptation to extrapolate these results to situations in which in vivo vascular injury occurs is tempered by the artificiality of our in vitro system. The actual meaning of endothelial 51Cr (or ["4C]thymidine) release is not clear. Our previous studies (8, 11) , which used a confirmatory assay of cytotoxicity (that of fluorochromasia), did support the suggestion that radiolabel release, at least in part, represents true cytotoxicity. However, other possibilities such as enhanced endothelial membrane turnover or nonlethal cellular "leak" are not completely excluded. In addition, others using similar, but not identical, endothelial cell culture systems have suggested that released granulocyte proteases may cause endothelial cell detachment from culture dishes rather than cell death (29) . We believe this formulation unlikely in our studies because our assay methods recapture detached, intact cells by centrifugation of culture supernates and include their radioactivity with that of the cell contents. The assay medium contains serum or plasma that inhibits endothelial-detaching proteases released by complement-stimulated granulocytes (29) . In fact, only 2-10% of the cell-associated radioactivity usually detached during the assay. There was no relationship between cellular detachment and soluble 51Cr release in the presence or absence of serotonin in the assay mixture (not shown).
With this caveat, our studies suggest that platelets that become adherent to sites of in vivo endothelial injury might by their release of serotonin (and other constituents) promote adhesion of granulocytes to the same or neighboring sites. If these granulocytes are or subsequently become stimulated, as by exposure to activated complement, further endothelial injury might supervene. Although this formulation-particularly the role of serotonin in vascular injury-will need to be validated by further experiments, it has not escaped our attention that hyperserotoninemic individuals with the carcinoid syndrome develop pulmonary arteriosclerosis in addition to rightsided endocardial damage. (30, 31) .
